“Multiple Myeloma Pipeline Insight, 2026″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple Myeloma Market.
The Multiple Myeloma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Get a Free Sample PDF Report to know more about Multiple Myeloma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight
Some of the key takeaways from the Multiple Myeloma Pipeline Report:
Companies across the globe are diligently working toward developing novel Multiple Myeloma treatment therapies with a considerable amount of success over the years.
Multiple Myeloma companies working in the treatment market are Regeneron Pharmaceuticals, Sanofi, Arcellx, Gilead, AbbVie, Bristol-Myers Squibb, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento Therapeutics, Johnson & Johnson Innovative Medicine, Bluebird bio, Sanofi, and others, are developing therapies for the Multiple Myeloma treatment
Emerging Multiple Myeloma therapies in the different phases of clinical trials are- TeneoOne, linvoseltamab, SARCLISA (isatuximab-irfc), Anito-cel (anitocabtagene autoleucel; formerly CART ddBCMA), Etentamig (ABBV-383/TNB-383B), BMS-986393 (CC-95266), Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, CARVYKTI (ciltacabtagene autoleucel) TALVEY (talquetamab), ABECMA, SARCLISA, and others are expected to have a significant impact on the Multiple Myeloma market in the coming years.
In June 2026, Long-term findings from the TEC-3 study showed that the combination of teclistamab and daratumumab achieved sustained progression-free survival in patients with first-relapse multiple myeloma, reinforcing the potential of bispecific antibodies in earlier lines of treatment. Recent hematology conferences also highlighted continued progress in CAR-T cell therapies and minimal residual disease (MRD)-guided treatment strategies, reflecting ongoing advancements in the multiple myeloma therapeutic landscape.
In May 2026,New clinical data for Tecvayli (teclistamab-cqyv) demonstrate significant survival benefits when the drug is used early in treatment, specifically at a patient’s first relapse with multiple myeloma. The findings show that Tecvayli—a bispecific antibody targeting BCMA and CD3 receptors delivers superior progression-free survival (PFS) and overall survival (OS) compared to standard multi-drug regimens. Historically reserved for later lines of therapy after patients exhausted multiple options, these data argue strongly for moving Tecvayli up the treatment algorithm. By intervening during the first relapse, clinicians can achieve deeper, more durable remissions, offering a substantial clinical advantage to patients before their disease mutates and becomes highly resistant.
In April 2026, Opna Bio has been granted FDA Fast Track Designation for OPN-6602, a dual EP300/CBP inhibitor, for the treatment of patients with relapsed or refractory multiple myeloma who have undergone at least four prior lines of therapy. The designation is intended to expedite the clinical development and regulatory review of this promising epigenetic therapy.
In March 2026, The U.S. FDA approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj for the treatment of adults with relapsed or refractory multiple myeloma who have previously received at least one line of therapy, including a proteasome inhibitor and an immunomodulatory agent. This approval broadens the use of BCMA-targeted bispecific antibody therapy, enabling its adoption in earlier stages of the multiple myeloma treatment pathway.
In March 2026, The U.S. Food and Drug Administration has approved the combination of teclistamab (Tecvayli) and daratumumab hyaluronidase-fihj (Darzalex Faspro) for the treatment of adults with Relapsed or Refractory Multiple Myeloma (RRMM) who have previously undergone at least one line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
In March 2026, Johnson & Johnson (NYSE: JNJ), a global leader in multiple myeloma treatments, announced that the U.S. Food and Drug Administration (FDA) has approved a combination therapy of TECVAYLI (teclistamab-cqyv) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for adults with Relapsed or Refractory Multiple Myeloma (RRMM) who have previously received at least one line of treatment, including a proteasome inhibitor and an immunomodulatory agent. This combination works synergistically to stimulate and activate the immune system, enabling it to target and eliminate myeloma cells expressing the BCMA protein. The approval introduces a promising new treatment option that could potentially serve as a standard of care as early as second-line therapy, addressing the unmet needs of patients, particularly the nearly 40% who experience disease relapse.
In February 2026, AstraZeneca announced that the Phase II (DURGA-3) trial data is projected to be read out in H1 2026, followed by results from the Phase I (DURGA-2) study in H2 2026 and the Phase I/II (DURGA-1) trial in 2027.
In January 2026, Exicure announced the presentation of a poster at the 2026 Transplantation & Cellular Therapy Meetings, jointly organized by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). The presentation featured findings from the company’s open-label, multicenter Phase II trial (NCT05561751) evaluating burixafor in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation (AHCT).
In December 2025, CellCentric announced new data from dose optimization cohorts of its Phase II clinical trial of inobrodib in combination with pomalidomide and dexamethasone in heavily pretreated patients with RRMM. Presented during a poster session at the ASH annual meeting, the data further validate a compelling efficacy and safety profile for the all-oral InoPd regimen, including in patients with high-risk disease and prior exposure to TCEs and BCMA-targeted therapies.
Multiple Myeloma Overview
Multiple Myeloma is a type of blood cancer that develops in plasma cells, a type of white blood cell found in the bone marrow that produces antibodies to help fight infections. In multiple myeloma, abnormal plasma cells multiply uncontrollably, crowding out healthy blood cells and producing excessive amounts of abnormal proteins.
Explore the latest Multiple Myeloma pipeline insights 2026, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Multiple Myeloma Clinical Trials
Emerging Multiple Myeloma Drugs Under Different Phases of Clinical Development Include:
LYNOZYFIC (linvoseltamab): Regeneron Pharmaceuticals
SARCLISA (isatuximab-irfc): Sanofi
Anito-cel (anitocabtagene autoleucel; formerly CART ddBCMA): Arcellx/Gilead (Kite)
Etentamig (ABBV-383/TNB-383B): AbbVie (TeneoOne)
BMS-986393 (CC-95266): Bristol-Myers Squibb
Zevorcabtagene Autoleucel: Carsgen Therapeutics
Descartes 08: Cartesian Therapeutics
GC012F: Gracell Biotechnology Shanghai Co., Ltd.
CID-103: CASI Pharmaceuticals
STI-1492: Sorrento Therapeutics
CARVYKTI (ciltacabtagene autoleucel): Johnson & Johnson Innovative Medicine
TALVEY (talquetamab): Johnson & Johnson Innovative Medicine
ABECMA: Bristol-Myers Squibb and Bluebird bio
SARCLISA: Sanofi
Multiple Myeloma Route of Administration
Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Subcutaneous
Intravenous
Oral
Intramuscular
Molecule Type
Multiple Myeloma Molecule Type
Multiple Myeloma Products have been categorized under various Molecule types, such as
Small molecules
Natural metabolites
Monoclonal antibodies
Product Type
Multiple Myeloma Pipeline Therapeutics Assessment
Multiple Myeloma Assessment by Product Type
Multiple Myeloma By Stage and Product Type
Multiple Myeloma Assessment by Route of Administration
Multiple Myeloma By Stage and Route of Administration
Multiple Myeloma Assessment by Molecule Type
Multiple Myeloma by Stage and Molecule Type
DelveInsight’s Multiple Myeloma Report covers around 80+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Multiple Myeloma product details are provided in the report. Download the Multiple Myeloma pipeline report to learn more about the emerging Multiple Myeloma therapies
Some of the key companies in the Multiple Myeloma Therapeutics Market include:
Key companies developing therapies for Multiple Myeloma are – Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics, Juno Therapeutics, CRISPR Therapeutics, Celyad Oncology, Allogene Therapeutics, Gadeta, Nanjing IASO Biotherapeutics, and others.
Multiple Myeloma Pipeline Analysis:
The Multiple Myeloma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Myeloma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Myeloma Treatment.
Multiple Myeloma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Myeloma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Multiple Myeloma drugs and therapies
Multiple Myeloma Pipeline Market Drivers
Rising global prevalence of multiple myeloma and an expanding aging population, increasing the demand for innovative therapies.
Robust pipeline of CAR-T cell therapies, bispecific antibodies, antibody-drug conjugates (ADCs), and next-generation immunotherapies.
Increasing regulatory support through Breakthrough Therapy, Fast Track, Priority Review, and Orphan Drug designations for promising candidates.
Growing adoption of precision medicine and biomarker-driven treatment strategies to improve patient outcomes.
Continuous advancements in BCMA-targeted therapies and novel immunotherapeutic approaches for relapsed and refractory multiple myeloma.
Multiple Myeloma Pipeline Market Barriers
High development costs and lengthy clinical trial timelines for advanced biologics and cell-based therapies.
Complex manufacturing, scalability, and supply chain challenges associated with CAR-T cell therapies and personalized treatments.
Emergence of treatment resistance and disease relapse, limiting long-term therapeutic efficacy.
Safety concerns, including cytokine release syndrome (CRS), neurotoxicity, and other immune-related adverse events.
Intense market competition among multiple BCMA-targeted therapies and next-generation immunotherapies.
Scope of Multiple Myeloma Pipeline Drug Insight
Coverage: Global
Key Multiple Myeloma Companies: Regeneron Pharmaceuticals, Sanofi, Arcellx, Gilead, AbbVie, Bristol-Myers Squibb, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento Therapeutics, Johnson & Johnson Innovative Medicine, Bluebird bio, Sanofi, and others
Key Multiple Myeloma Therapies: TeneoOne, linvoseltamab, SARCLISA (isatuximab-irfc), Anito-cel (anitocabtagene autoleucel; formerly CART ddBCMA), Etentamig (ABBV-383/TNB-383B), BMS-986393 (CC-95266), Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, CARVYKTI (ciltacabtagene autoleucel) TALVEY (talquetamab), ABECMA, SARCLISA, and others
Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies
Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and Multiple Myeloma market barriers
Request for Sample PDF Report for Multiple Myeloma Pipeline Assessment and clinical trials
Table of Contents
1. Multiple Myeloma Report Introduction
2. Multiple Myeloma Executive Summary
3. Multiple Myeloma Overview
4. Multiple Myeloma- Analytical Perspective In-depth Commercial Assessment
5. Multiple Myeloma Pipeline Therapeutics
6. Multiple Myeloma Late Stage Products (Phase II/III)
7. Multiple Myeloma Mid Stage Products (Phase II)
8. Multiple Myeloma Early Stage Products (Phase I)
9. Multiple Myeloma Preclinical Stage Products
10. Multiple Myeloma Therapeutics Assessment
11. Multiple Myeloma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Multiple Myeloma Key Companies
14. Multiple Myeloma Key Products
15. Multiple Myeloma Unmet Needs
16 . Multiple Myeloma Market Drivers and Barriers
17. Multiple Myeloma Future Perspectives and Conclusion
18. Multiple Myeloma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
